The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Brady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Kabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Petrelli, N., Douglass, H. O., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., & Muggia, F. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1419 · Cited by 556
Herbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein, G., Lee, J. J., Liu, D. D., Truong, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.477 · Cited by 530
Santoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., Buesa, J., Casali, P., Spooner, D., & Rankin, E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1537 · Cited by 526
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Kindler, H. L., Friberg, G., Singh, D. A., Locker, G., Nattam, S., Kozloff, M., Taber, D. A., Karrison, T., Dachman, A., Stadler, W. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9661 · Cited by 460
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004) · Angiogenesis · doi:10.1007/s10456-004-8272-2 · Cited by 430
Role of Vascular Endothelial Growth Factor in Ovarian Cancer
Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392
Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A. S., Kabbinavar, F., Holden, S. N., Novotny, W. F., Frantz, G. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5388 · Cited by 387
Schneider, B. P., & Miller, K. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.017 · Cited by 350
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Kelly, H., & Goldberg, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.749 · Cited by 316
Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., & Greco, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8234 · Cited by 303
Turner, K., Moore, J. W., Jones, A., Taylor, C., Cuthbert-Heavens, D., Cheng, H., Leek, R., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., et al. (2002) · PubMed · Cited by 303
VEGF165 mediates glomerular endothelial repair
Ostendorf, T., Kunter, U., Eitner, F., Loos, A., Regele, H., Kerjaschki, D., Henninger, D. D., Janjic, N., & Floege, J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6740 · Cited by 287
Petrelli, N., Douglass, H. O., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., Muggia, F. M., et al. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.185 · Cited by 280
Rosen, L. S. (2002) · Cancer Control · doi:10.1177/107327480200902s05 · Cited by 268
Lin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas
D'Adamo, D. R., Anderson, S. E., Albritton, K., Yamada, J., Riedel, E., Scheu, K., Schwartz, G. K., Chen, H., & Maki, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.139 · Cited by 252
Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications
Herbst, R. S., Onn, A., & Sandler, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.853 · Cited by 246
Itakura, J., Ishiwata, T., Shen, B., Kornmann, M., & Korc, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000101)85:1<27::aid-ijc5>3.0.co;2-8 · Cited by 234
Di Maio, M., Gridelli, C., Gallo, C., Shepherd, F., Piantedosi, F. V., Cigolari, S., Manzione, L., Illiano, A., Barbera, S., Robbiati, S. F., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70255-2 · Cited by 234
Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria
Park, J. O. (2003) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyg093 · Cited by 222
Gasparini, G., Longo, R., Fanelli, M., & Teicher, B. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.022 · Cited by 200
Baker, C. H., Solórzano, C. C., & Fidler, I. J. (2002) · PubMed · Cited by 196
Borgström, P., Gold, D. P., Hillan, K. J., & Ferrara, N. (1999) · PubMed · Cited by 196
Angiogenic growth factors and hypertension
Sane, D. C., Anton, L., & Brosnihan, K. B. (2004) · Angiogenesis · doi:10.1007/s10456-004-2699-3 · Cited by 195
Akagi, Y., Liu, W., Zebrowski, B. K., Xie, K., & Ellis, L. M. (1998) · PubMed · Cited by 184
Saltz, L. B., Lenz, H.-J., Hochster, H., Wadler, S., Hoff, P., Kemeny, N., Hollywood, E., Gonen, M., Wetherbee, S., & Chen, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3508 · Cited by 183
Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Venook, A. P. (2005) · The Oncologist · doi:10.1634/theoncologist.10-4-250 · Cited by 170
MELNYK, O., ZIMMERMAN, M., KIM, K. J., & SHUMAN, M. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61829-9 · Cited by 162
VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances
Rosen, L. S. (2005) · The Oncologist · doi:10.1634/theoncologist.10-6-382 · Cited by 147
Bruns, C. J., Shrader, M., Harbison, M. T., Portera, C. A., Solórzano, C. C., Jauch, K. ‐., Hicklin, D. J., Radinsky, R., & Ellis, L. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10681 · Cited by 146
Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies
Zondor, S. D., & Medina, P. J. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d470 · Cited by 135
Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas
Passalidou, E., Trivella, M., Singh, N., Ferguson, M. L., Hu, J., Cesario, A., Granone, P. L., Nicholson, A. G., Goldstraw, P. G., Ratcliffe, C., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600015 · Cited by 125
Two Steps Forward in the Treatment of Colorectal Cancer
Mayer, R. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048098 · Cited by 116
Bevacizumab in the Treatment of Breast Cancer: Rationale and Current Data
Rugo, H. S. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-43 · Cited by 108
Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab
Fernando, N. H., & Hurwitz, H. I. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-11 · Cited by 107
Genentech discloses safety concerns over Avastin
Ratner, M. (2004) · Nature Biotechnology · doi:10.1038/nbt1004-1198 · Cited by 101
Giles, F. J. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2004-32 · Cited by 99
Bevacizumab—current status and future directions
Midgley, R. S., & Kerr, R. S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi208 · Cited by 96
Hedrick, E. E., Kozloff, M. F., Hainsworth, J. D., Badarinath, S., Cohn, A. L., Flynn, P. J., Dong, W., Suzuki, S., Sugrue, M. M., & Grothey, A. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3536 · Cited by 89
New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers
Díaz‐Rubio, E. (2004) · The Oncologist · doi:10.1634/theoncologist.9-3-282 · Cited by 84
Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)
Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K. T., Srinivas, S., Vaishampayan, U. N., Drabkin, H. A., Dutcher, J. P., Scappaticci, F. A., & McDermott, D. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4523 · Cited by 82
Angiogenic factors as tumor markers
Nguyen, M. T. N. (1997) · Investigational New Drugs · doi:10.1023/a:1005766511385 · Cited by 80
Ushijima, C., Tsukamoto, S., Yamazaki, K., Yoshino, I., Sugio, K., & Sugimachi, K. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00246-x · Cited by 73
Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?
Herbst, R. S., & Sandler, A. B. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-19 · Cited by 69
Novel treatment strategies in clear-cell metastatic renal cell carcinoma
van Spronsen, D. J., de Weijer, K., Mulders, P., & Mulder, P. H. M. D. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167901.58877.a3 · Cited by 54
Bevacizumab in combination chemotherapy for colorectal and other cancers
Motl, S. E. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.10.1021 · Cited by 53
Blood flow influences vascular growth during tumour angiogenesis
Nasu, R., Kimura, H., Akagi, K., Murata, T., & Tanaka, Y. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690125 · Cited by 49
Translating angiogenesis research into the clinic: the challenges ahead
Augustin, H. G. (2003) · British Journal of Radiology · doi:10.1259/bjr/68078705 · Cited by 41
Expanding the Clinical Development of Bevacizumab
Chen, H. X. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-27 · Cited by 37
Fernando, N., Yu, D., Morse, M. A., Blobe, G. C., Odogwu, L., Crews, J. R., Polito, A., Honeycutt, W., Franklin, A., & Hurwitz, H. I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3556 · Cited by 37
Goldberg, R., & Gill, S. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0888-9 · Cited by 34
Cited by
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Rimkus, T., Carpenter, R., Qasem, S., Chan, M., & Lo, H.-W. (2016) · Cancers · doi:10.3390/cancers8020022 · Cited by 581
Cancer-associated adipocytes: key players in breast cancer progression
Wu, Q., Li, B., Li, Z., Li, J., Sun, S., & Sun, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0778-6 · Cited by 462
The Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 450
Secondary arterial hypertension: when, who, and how to screen?
Rimoldi, S. F., Scherrer, U., & Messerli, F. H. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht534 · Cited by 393
“200/100 mmHg) compared with placebo.(28,29) After 6 months of treatment with bevacizumab, SBP increased from 129 to 145 mmHg and in DBP from 75 to 82 mmHg.”
Method
Metadata
- Authors
- Shih, T., & Lindley, C.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 28
- Issue
- 11
- Pages
- 1779-1802
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2079150475
- Cited by
- 521
- References
- 79
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.